Bharat Book Bureau Provides the Trending Market Research Report on “Global Traveler's Diarrhea Therapeutics Market Growth 2022-2028 “under Life Sciences category. The Global Traveler’s Diarrhea Therapeutics Market is projected to exhibit highest growth rate over report offers a collection of superior market research, market analysis, and competitive intelligence and industry reports.
As the global economy mends, the 2021 growth of Traveler's Diarrhea Therapeutics will have significant change from previous year. According to our (LP Information) latest study, the global Traveler's Diarrhea Therapeutics market size is USD million in 2022 from USD 768.3 million in 2021, with a change of % between 2021 and 2022. The global Traveler's Diarrhea Therapeutics market size will reach USD 1263.5 million in 2028, growing at a CAGR of 7.4% over the analysis period.
The United States Traveler's Diarrhea Therapeutics market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Traveler's Diarrhea Therapeutics market, reaching US$ million by the year 2028. As for the Europe Traveler's Diarrhea Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Traveler's Diarrhea Therapeutics players cover Salix Pharmaceuticals, P&G, Johnson & Johnson, and Otsuka Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Traveler's Diarrhea Therapeutics market by product type, application, key manufacturers and key regions and countries.
Segmentation by type:
breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Immunization
Non-antibiotic Agents
Antibiotics
Anti-Motility Agents
Others
Segmentation by application:
breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Adult Traveler's Diarrhea
Children Traveler's Diarrhea
This report also splits the market by region:
Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Salix Pharmaceuticals
P&G
Johnson & Johnson
Otsuka Pharma
Valneva
Shanghai United Cell
PaxVax
Livzon
Immuron
Browse our full report with Table of Contents:
https://www.bharatbook.com/report/1165027/global-travelers-diarrhea-therapeutics-market-growth
About Us
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 15,00,000 reports and insights that includes latest Industry Study, Industry Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the diarrhea market include Abbott Laboratories, Aidarex Pharmaceuticals LLC, Atlantic Biologicals Corps, Major Pharmaceuticals, Proficient Rx LP, Chattem Inc., V.Excel International, ANI Pharmaceuticals Inc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Diarrhea Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/diarrhea-market/download-sampleMarket DynamicsThe high prevalence of diarrhea among the global population is the main driver for the market’s growth.
Changing lifestyles and food habits, and diarrhea becoming more common among children will benefit the market growth.
The rapid proliferation of healthcare facilities, availability of better diagnostic systems, and raising awareness will further propel market growth.
An increase in the number of globe trotters and the flourishing tourism industry can be a source of income for the market.
Traveler’s Diarrhea Treatment Market is a digestive tract disorder characterized by an intestinal infection that generally occurs when a person consume contaminated food and water.
This infection generally spreads through intestinal pathogens contracted while traveling where here the climatic conditions and sanitary practices are different from their home.
Symptoms include loose stools, abdominal cramps, nausea and vomiting.Traveler's diarrhea treatment market is growing at a substantial CAGR of 7.4% in the forecast period of 2020-2027.
Get Sample Report at : https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-travelers-diarrhea-treatment-marketCompetitive Analysis: Global Traveler’s Diarrhea Treatment MarketThe key market players in the traveler's diarrhea treatment market are Bayer AG, Merck & Co., Inc, Johnson & Johnson Services, Inc, Novartis AG, Valneva SE, Shanghai United Cell Biotechnology Co.,Ltd, PaxVax, Inc, Immuron, Salix Pharmaceuticals, F. Hoffmann-La Roche Ltd, Basilea Pharmaceutica Ltd, Eli Lilly and Company, Delcath Systems Inc, BridgeBio Inc, Incyte Corporation, Agios, Inc among others.
Key Pointers Covered in the Global Traveler’s Diarrhea Treatment Market Trends and Forecast to 2026Global Traveler’s Diarrhea Treatment Market New Sales VolumesGlobal Traveler’s Diarrhea Treatment Market Replacement Sales VolumesGlobal Traveler’s Diarrhea Treatment Market Installed BaseGlobal Traveler’s Diarrhea Treatment Market By BrandsGlobal Traveler’s Diarrhea Treatment Market SizeGlobal Traveler’s Diarrhea Treatment Market Procedure VolumesGlobal Traveler’s Diarrhea Treatment Market Product Price AnalysisGlobal Traveler’s Diarrhea Treatment Market Healthcare OutcomesGlobal Traveler’s Diarrhea Treatment Market Cost of Care AnalysisGlobal Traveler’s Diarrhea Treatment Market Regulatory Framework and ChangesGlobal Traveler’s Diarrhea Treatment Market Prices and Reimbursement AnalysisGlobal Traveler’s Diarrhea Treatment Market Shares in Different RegionsRecent Developments for Global Traveler’s Diarrhea Treatment Market CompetitorsGlobal Traveler’s Diarrhea Treatment Market Upcoming ApplicationsGlobal Traveler’s Diarrhea Treatment Market Innovators StudyGet Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-travelers-diarrhea-treatment-market Key Developments in the Market:In November 2018, COSMO PHARMACEUTICALS received the U.S FDA approval for Aemcolo (rifamycin), an antibacterial drug indicated to treat adult patients with travelers’ diarrhea which is caused by noninvasive strains of Escherichia coli (E. coli).
The approval of Aemcolo can potentially change the treatment landscape and offers complete treatment for millions of people each year.In February 2019, Dr. Falk Pharma GmbH is developing SV-MMX (Rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea.
